Praxis Precision Medicines: Funding, Investors & Team (Sep 2026)
Praxis Precision Medicines is a company in the biopharmaceutical industry that focuses on developing treatments for central nervous system (CNS) disorders. They utilize genetic knowledge to address neuronal imbalances associated with these disorders. By leveraging their understanding of common biological targets and brain circuits, Praxis extends their research from genetic epilepsies to a wider range of neurological and psychiatric disorders.
Praxis Precision Medicines has raised $1.4B across 4 funding rounds on record, the most recent an undisclosed round of $575M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Praxis Precision Medicines Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Praxis Precision Medicines Funding Rounds
Praxis Precision Medicines raised $150M in an undisclosed round announced in Jan 2024.
2 months later, an undisclosed round of $200M was announced in Mar 2024.
1.6 years later, an undisclosed round of $525M was announced in Oct 2025.
3 months later, an undisclosed round of $575M was announced in Jan 2026.
Praxis Precision Medicines Founders and Leadership Team
Contact details for the Praxis Precision Medicines team: 1 of 1 has an email address on file.
Start 14-day free trial →Praxis Precision Medicines Funding Compared to Other Biotechnology Startups
Praxis Precision Medicines' latest round of $575M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Praxis Precision Medicines in Biotechnology and Cambridge
Companies Similar to Praxis Precision Medicines
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Praxis Precision Medicines Funding FAQs
What does Praxis Precision Medicines do?
Praxis Precision Medicines is a company in the biopharmaceutical industry that focuses on developing treatments for central nervous system (CNS) disorders. They utilize genetic knowledge to address neuronal imbalances associated with these disorders. By leveraging their understanding of common biological targets and brain circuits, Praxis extends their research from genetic epilepsies to a wider range of neurological and psychiatric disorders.
How much funding has Praxis Precision Medicines raised?
Praxis Precision Medicines has raised $1.4B across 4 rounds on record. The most recent is an undisclosed round of $575M announced in Jan 2026.
When did Praxis Precision Medicines last raise funding?
Praxis Precision Medicines' most recent funding round on record is an undisclosed round of $575M, announced in Jan 2026.
Who founded Praxis Precision Medicines?
FundedIQ lists Steven Petrou (Founder) at Praxis Precision Medicines.
Where is Praxis Precision Medicines headquartered?
Praxis Precision Medicines is based in Cambridge, Massachusetts, United States.
How many employees does Praxis Precision Medicines have?
Praxis Precision Medicines is in the 51-100 employee band.
How does Praxis Precision Medicines' funding compare to other Biotechnology startups?
Praxis Precision Medicines' latest round of $575M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Praxis Precision Medicines Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Praxis Precision Medicines is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.